Interleukin-10: An immune-activating cytokine in cancer immunotherapy

Journal of Clinical Oncology

Volumn 34, Issue 29, 2016, Pages 3576-3578

  Zhang, Hui ^a   Wang, Yu ^b   Hwang, E Shelley ^b   He, You Wen ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; CYTOKINE; INTERLEUKIN 2;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; IMMUNOTHERAPY; NEOPLASM;

CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-2; NEOPLASMS;

EID: 84990046448     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.6435     Document Type: Article

References (19)

1. Naing A, Papadopoulos KP, Autio KA, et al: Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34:3562-3569, 2016
2. Ouyang W, Rutz S, Crellin NK, et al: Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71-109, 2011
3. Mannino MH, Zhu Z, Xiao H, et al: The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367:103-107, 2015
4. Berg DJ, Davidson N, Kühn R, et al: Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98:1010-1020, 1996
5. Mumm JB, Emmerich J, Zhang X, et al: IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 20:781-796, 2011
6. Tanikawa T, Wilke CM, Kryczek I, et al: Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 72:420-429, 2012
7. Berman RM, Suzuki T, Tahara H, et al: Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 157:231-238, 1996
8. Fujii S, Shimizu K, Shimizu T, et al: Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 98:2143-2151, 2001
9. Emmerich J, Mumm JB, Chan IH, et al: IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 72:3570-3581, 2012
10. Wang L, Liu JQ, Talebian F, et al: IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4(+) T cells and promoting CTL persistence in a murine model of plasmacytoma. Oncoimmunology 4:e1014232, 2015
11. Chen WF, Zlotnik A: IL-10: A novel cytotoxic T cell differentiation factor. J Immunol 147:528-534, 1991
12. Yang G, Hellström KE, Mizuno MT, et al: In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 155:3897-3903, 1995
13. Groux H, Bigler M, de Vries JE, et al: Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 160:3188-3193, 1998
14. Santin AD, Hermonat PL, Ravaggi A, et al: Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74:4729-4737, 2000
15. Wang Y, Sun SN, Liu Q, et al: Autocrine complement inhibits IL10-dependent T-cell mediated antitumor immunity to promote tumor progression. Cancer Discov 10.1158/2159-8290.CD-15-1412 [epub ahead of print on June 13, 2016]
16. Miotto D, Lo Cascio N, Stendardo M, et al: CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer 69:355-360, 2010
17. Buchbinder EI, McDermott DF: Interferon, interleukin-2, and other cytokines. Hematol Oncol Clin North Am 28:571-583, 2014
18. Callahan MK, Postow MA, Wolchok JD: Targeting T cell co-receptors for cancer therapy. Immunity 44:1069-1078, 2016
19. Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015